Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: Probe of CYP3A

Therapeutic Drug Monitoring

Volumn 20, Issue 3, 1998, Pages 319-324

  Carrillo, Juan A ^a   Ramos, Sara I ^a   Agundez, Jose A G ^a   Martinez, Carmen ^a   Benitez, Julio ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

CYP3A; High performance liquid chromatography; Metabolites; Midazolam

Indexed keywords

4 HYDROXYMIDAZOLAM; ALPHA HYDROXYMIDAZOLAM; AMITRIPTYLINE; BENTAZEPAM; BROMAZEPAM; BROTIZOLAM; CAFFEINE; CHLORPROMAZINE; CIMETIDINE; CLOMIPRAMINE; CLONAZEPAM; CLORAZEPATE; CLOZAPINE; CYTOCHROME C OXIDASE; DESIPRAMINE; DIAZEPAM; DOXEPIN; DRUG METABOLITE; EBROTIDINE; FLUNITRAZEPAM; FLUPHENAZINE; HALOPERIDOL; IMIPRAMINE; KETOCONAZOLE; LORAZEPAM; MIDAZOLAM MALEATE; NORTRIPTYLINE; PARACETAMOL; PHENYTOIN; QUINIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT; ANESTHESIA INDUCTION; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG MONITORING; ENZYME ACTIVITY; ENZYME POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEDATION;

EID: 0031811037     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199806000-00013     Document Type: Article

References (25)

1. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
2. Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996;60: 14-24.
3. Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism, Clin Pharmacol Ther 1996;59: 491-502.
4. Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305.
5. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-5.
6. Ring BJ, Binkley SN, Roskos L, Wrighton SA. Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1'-hydroxy midazolam formation in vitro. J Pharmacol Exp Ther 1995;275:1131-5.
7. Von Moltke LL, Greenblatt DJ, Schmider J, et al. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996;36:783-91.
8. Wrighton SA, Ring BJ. Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm Res 1994;11: 921-4.
9. Jurima Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver: In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 1994;22:849-57.
10. Villikka K, Kivistö KT, Backman JT, Olkkola KT, Neuvonen PJ. Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther 1997;61:8-14.
11. Von Rosensteil NA, Adam D. Macrolide antibacterials: Drug interactions of clinical significance. Drug Saf 1995;13:105-22.
12. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996;59:7-13.
13. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-84.
14. Watkins PB, Turgeon DK, Saenger P, et al. Comparison of urinary 6-β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 1992;52: 265-73.
15. Stein CM, Kinirons MT, Pincus T, Wilkinson GR, Wood AJJ. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Clin Pharmacol Ther 1996;59:47-51.
16. Burtin P, Jacqz Aigrain E, Girard P, et al. Population pharmacokinetics of midazolam in neonates. Clin Pharmacol Ther 1994;56: 615-25.
17. Malacrida R, Fritz ME, Suter PM, Crevoisier C. Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients. Crit Care Med 1992;20:1123-6.
18. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989;36:89-96.
19. Ghosal A, Satoh H, Thomas PE, Bush E, Moore D. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. Drug Metab Dispos 1996;24:940-7.
20. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994;47:1643-53.
21. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15:387-98.
22. Watkins PB. Cyclosporine and liver transplantation: will the midazolam test make blood level monitoring obsolete? Hepatology 1995;2:994-6.
23. Lown KS, Thummel KE, Benedict PE, et al. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995;57:16-24.
24. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe, I: In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-56.
25. Ha HR, Rentsch KM, Kneer J, Vonderschmitt DJ. Determination of midazolam and its a-hydroxymetabolite in human plasma and urine by high-performance liquid chromatography. Ther Drug Monit 1993;15:338-43.